Bridging Early Development and Scalable Manufacturing in Adenovirus Production
Available On Demand, 45 minutes
Adenovirus-based therapies show strong potential, but translating early-stage processes into scalable, robust manufacturing remains a critical challenge. Systems that perform well at the benchtop can become inefficient or inconsistent at a larger scale, while adherent cell culture formats can limit scalability and commercial readiness.
In this on-demand webinar, Kelly Tran, Manager, Upstream Viral Vector Process Development at SK pharmteco, shares how our team supports adenovirus programs from early development through to manufacturing scale. Drawing on project experience, Kelly discusses practical approaches to process optimization, scale-up, and platform adaptation to enable efficient, high-quality production.
What You’ll Learn
- How to optimize adenovirus processes in early development to support scalable manufacturing
- Key considerations when scaling from benchtop systems to manufacturing bioreactors
- Strategies for transitioning from adherent to suspension platforms while maintaining product quality
- Real-world challenges in adenovirus manufacturing and approaches to address them
View the on-demand webinar:
Presenter: Kelly Tran, Manager, Upstream Viral Vector Process Development, SK pharmteco Viral Vector North America